Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Merus

Nasdaq:MRUS
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MRUS
Nasdaq
$360M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. The last earnings update was 12 days ago. More info.


Add to Portfolio Compare Print
  • Merus has significant price volatility in the past 3 months.
MRUS Share Price and Events
7 Day Returns
3.2%
NasdaqGM:MRUS
6.3%
US Biotechs
12.6%
US Market
1 Year Returns
-16%
NasdaqGM:MRUS
1.6%
US Biotechs
-9.1%
US Market
MRUS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Merus (MRUS) 3.2% -25.9% -19.3% -16% -49.2% -
US Biotechs 6.3% -7.9% -7.9% 1.6% 7.7% -8.8%
US Market 12.6% -16.7% -19.6% -9.1% 8.2% 21.5%
1 Year Return vs Industry and Market
  • MRUS underperformed the Biotechs industry which returned 1.6% over the past year.
  • MRUS underperformed the Market in United States of America which returned -9.1% over the past year.
Price Volatility
MRUS
Industry
5yr Volatility vs Market

Value

 Is Merus undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Merus. This is due to cash flow or dividend data being unavailable. The share price is $12.4.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Merus's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Merus's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:MRUS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-2.28
NasdaqGM:MRUS Share Price ** NasdaqGM (2020-03-27) in USD $12.4
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.87x
United States of America Market PE Ratio Median Figure of 2,935 Publicly-Listed Companies 13.38x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Merus.

NasdaqGM:MRUS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:MRUS Share Price ÷ EPS (both in USD)

= 12.4 ÷ -2.28

-5.45x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Merus is loss making, we can't compare its value to the US Biotechs industry average.
  • Merus is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Merus's expected growth come at a high price?
Raw Data
NasdaqGM:MRUS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.45x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
21.4%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.99x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1.03x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Merus, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Merus's assets?
Raw Data
NasdaqGM:MRUS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $4.55
NasdaqGM:MRUS Share Price * NasdaqGM (2020-03-27) in USD $12.4
United States of America Biotechs Industry PB Ratio Median Figure of 428 Publicly-Listed Biotechs Companies 2.47x
United States of America Market PB Ratio Median Figure of 5,145 Publicly-Listed Companies 1.27x
NasdaqGM:MRUS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:MRUS Share Price ÷ Book Value per Share (both in USD)

= 12.4 ÷ 4.55

2.73x

* Primary Listing of Merus.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Merus is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Merus's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Merus has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Merus expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
21.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Merus expected to grow at an attractive rate?
  • Merus's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • Merus's earnings growth is expected to exceed the United States of America market average.
  • Merus's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:MRUS Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:MRUS Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 21.4%
NasdaqGM:MRUS Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 47.9%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.7%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:MRUS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:MRUS Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 351 49 4
2023-12-31 155 -81 4
2022-12-31 62 -91 5
2021-12-31 43 -86 6
2020-12-31 36 -50 -77 6
2020-03-28
NasdaqGM:MRUS Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 31 -63 -55
2019-09-30 33 -54 -30
2019-06-30 32 -59 -33
2019-03-31 33 -44 -25
2018-12-31 38 -46 -28
2018-09-30 34 -46 -41
2018-06-30 33 -43 -45
2018-03-31 34 -54 -66
2017-12-31 26 -45 -78
2017-09-30 18 -44 -100
2017-06-30 12 -33 -87
2017-03-31 6 -27 -66

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Merus's earnings are expected to grow significantly at over 20% yearly.
  • Merus's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:MRUS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Merus Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:MRUS Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 0.99 5.13 -2.64 4.00
2023-12-31 -2.04 -1.78 -2.45 3.00
2022-12-31 -2.41 -1.53 -3.17 4.00
2021-12-31 -2.60 -1.42 -3.34 6.00
2020-12-31 -2.78 -2.76 -2.80 3.00
2020-03-28
NasdaqGM:MRUS Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -2.28
2019-09-30 -1.27
2019-06-30 -1.45
2019-03-31 -1.08
2018-12-31 -1.27
2018-09-30 -1.94
2018-06-30 -2.18
2018-03-31 -3.33
2017-12-31 -4.05
2017-09-30 -5.47
2017-06-30 -4.96
2017-03-31 -4.19

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Merus will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Merus's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Merus has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Merus performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Merus's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Merus does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Merus's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Merus's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Merus's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Merus Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:MRUS Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 31.13 -55.15 34.11
2019-09-30 32.57 -29.52 11.82
2019-06-30 32.16 -33.50 12.03
2019-03-31 32.80 -24.74 11.20
2018-12-31 38.38 -28.31 29.35
2018-09-30 33.75 -41.49 12.70
2018-06-30 32.97 -44.89 14.00
2018-03-31 34.44 -65.89 16.02
2017-12-31 26.31 -77.78 17.20
2017-09-30 18.00 -100.39 17.90
2017-06-30 12.43 -86.95 13.47
2017-03-31 6.15 -65.75 9.20
2016-12-31 2.65 -50.08 5.09
2016-09-30 3.93 -24.65 2.17
2016-06-30 2.95 -25.68 1.60
2016-03-31 3.09 -27.12 1.25
2015-12-31 2.07 -25.26 1.02
2015-09-30 2.39 -24.87 0.61
2015-06-30 2.49 -23.11 -0.71
2015-03-31 1.34 -20.10 -0.03
2014-12-31 1.58 -21.07 0.67
2013-12-31 0.77 -13.64 3.93

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Merus has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Merus has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Merus improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Merus's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Merus has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Merus's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Merus's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Merus is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Merus's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Merus's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Merus has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Merus Company Filings, last reported 2 months ago.

NasdaqGM:MRUS Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 131.30 0.00 239.77
2019-09-30 76.74 0.00 171.76
2019-06-30 87.36 0.00 190.66
2019-03-31 97.61 0.00 203.75
2018-12-31 105.86 0.00 235.35
2018-09-30 98.67 0.00 224.35
2018-06-30 108.36 0.00 241.98
2018-03-31 117.49 0.00 251.77
2017-12-31 67.95 0.00 220.61
2017-09-30 70.61 0.00 239.24
2017-06-30 83.01 0.00 246.19
2017-03-31 97.61 0.00 252.90
2016-12-31 36.34 0.51 60.08
2016-09-30 71.64 0.61 74.49
2016-06-30 75.92 0.65 79.01
2016-03-31 26.41 0.71 29.79
2015-12-31 30.74 0.71 35.68
2015-09-30 38.10 0.79 44.76
2015-06-30 -9.35 9.29 7.32
2015-03-31 -3.82 0.88 1.68
2014-12-31 -4.31 0.99 1.90
2013-12-31 10.55 1.36 14.66
  • Merus has no debt.
  • Merus currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Merus has sufficient cash runway for more than 3 years based on current free cash flow.
  • Merus has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 24.8% each year.
X
Financial health checks
We assess Merus's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Merus has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Merus's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Merus dividends. Estimated to be 0% next year.
If you bought $2,000 of Merus shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Merus's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Merus's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:MRUS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1956 Stocks 2.9%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.9%
United States of America Top 25% Dividend Yield 75th Percentile 5.3%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:MRUS Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Merus has not reported any payouts.
  • Unable to verify if Merus's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Merus's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Merus has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Merus's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Merus's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Merus afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Merus has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Merus's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Bill Lundberg
AGE 56
TENURE AS CEO 0.3 years
CEO Bio

Dr. Sven Ante Lundberg, also known as Bill, MD serves as Chief Executive Officer, President of Merus N.V. since December 31, 2019 and served as its Principal Financial Officer. He served as Non-Executive Director at Merus N.V. from June 2019 until January 2020 and has been its Executive Director since January 2020 & served as its Board Observer from March 2019 to June 2019. Dr. Lundberg has been Head of Scientific Advisory Board at CRISPR Therapeutics AG since February 8, 2018. Dr. Lundberg has been Director of Alliance for Regenerative Medicine since 2018. Dr. Lundberg served as Chief Scientific Officer of CRISPR Therapeutics AG from February 2015 to February 8, 2018. Dr. Lundberg served as Head of Translational Medicine and Vice President at Alexion Pharmaceuticals, Inc. Dr. Lundberg has a wealth of knowledge and experience in the fields of immunology and oncology. Dr. Lundberg served as Chief Medical Officer of Taligen Therapeutics, Inc. since April 2010. Dr. Lundberg has held senior clinical and medical affairs roles in both large pharmaceutical and emerging biopharmaceutical companies, including Genzyme, Pfizer (formerly, Wyeth), Xanthus Pharmaceuticals and Antisoma Research Ltd. Dr. Lundberg received clinical training in internal medicine and oncology at Brigham and Women's Hospital and Dana-Farber Cancer Institute, both at Harvard Medical School and has held Research and Clinical Fellowship positions in Immunology and Oncology at the Dana-Farber Cancer Institute (Harvard Medical School) and the Whitehead Institute (MIT). Dr. Lundberg holds a B.S. degree in Biology from the Massachusetts Institute of Technology and an MD from Stanford Medical School. Dr. Lundberg has an MBA from the University of Massachusetts Amherst. He completed post-doctoral training at the Whitehead Institute/MIT.

CEO Compensation
  • Insufficient data for Bill to compare compensation growth.
  • Insufficient data for Bill to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Merus management team in years:

2.1
Average Tenure
52
Average Age
  • The tenure for the Merus management team is about average.
Management Team

Hui Liu

TITLE
CFO, Chief Business Officer
COMPENSATION
$815K
AGE
52

John de Kruif

TITLE
CTO & Senior VP
COMPENSATION
$532K
AGE
55
TENURE
7.2 yrs

Mark Throsby

TITLE
Chief Scientific Officer & Executive VP
COMPENSATION
$873K
AGE
52
TENURE
7.2 yrs

Peter Silverman

TITLE
Executive VP
COMPENSATION
$553K
AGE
41
TENURE
2.1 yrs

Ton Logtenberg

TITLE
Senior Advisor
COMPENSATION
$2M
AGE
61
TENURE
0.3 yrs

Lex Bakker

TITLE
CDO & Senior VP
COMPENSATION
$565K
AGE
52

L. Sirulnik

TITLE
Chief Medical Officer & Executive VP
COMPENSATION
$910K
AGE
52
TENURE
3.4 yrs

Bill Lundberg

TITLE
CEO, President & Executive Director
AGE
56
TENURE
0.3 yrs

Hennie Hoogenboom

TITLE
Co-Founder and Scientific Advisor

Jillian Connell

TITLE
Vice President of Investor Relations & Corporate Communications
TENURE
1.5 yrs
Board of Directors Tenure

Average tenure and age of the Merus board of directors in years:

1.9
Average Tenure
57
Average Age
  • The average tenure for the Merus board of directors is less than 3 years, this suggests a new board.
Board of Directors

Russell Greig

TITLE
Chairman of the Board
COMPENSATION
$161K
AGE
67
TENURE
1.7 yrs

Bill Lundberg

TITLE
CEO, President & Executive Director
AGE
56
TENURE
0.8 yrs

Mark Iwicki

TITLE
Non Executive Director
COMPENSATION
$115K
AGE
53
TENURE
4.8 yrs

Greg Perry

TITLE
Non-Executive Director
COMPENSATION
$105K
AGE
59
TENURE
3.8 yrs

John de Koning

TITLE
Non-Executive Director
COMPENSATION
$100K
AGE
50
TENURE
10.2 yrs

Elaine Jones

TITLE
Board Observer
AGE
64
TENURE
10.2 yrs

Anand Mehra

TITLE
Non-Executive Director
COMPENSATION
$99K
AGE
43
TENURE
2.2 yrs

Len Kanavy

TITLE
Non-Executive Director
COMPENSATION
$85K
AGE
57
TENURE
1.7 yrs

Hans Clevers

TITLE
Member of Scientific Advisory Board
AGE
62
TENURE
1.6 yrs

Toni Ribas

TITLE
Member of Scientific Advisory Board
TENURE
1.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
21. Jan 20 Buy BVF Partners LP Company 16. Jan 20 16. Jan 20 278,730 $16.15 $4,501,490
15. Jan 20 Buy BVF Partners LP Company 13. Jan 20 13. Jan 20 83,962 $14.98 $1,257,616
X
Management checks
We assess Merus's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Merus has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

How Much Of Merus N.V. (NASDAQ:MRUS) Do Institutions Own?

As you can see, institutional investors own 22% of Merus. … Insider Ownership Of Merus The definition of company insiders can be subjective, and does vary between jurisdictions. … Public Company Ownership We can see that public companies hold 15%, of the MRUS shares on issue.

Simply Wall St -

Should You Worry About Merus N.V.'s (NASDAQ:MRUS) CEO Salary Level?

First, this article will compare CEO compensation with compensation at similar sized companies. … View our latest analysis for Merus How Does Ton Logtenberg's Compensation Compare With Similar Sized Companies? … We compared the total CEO remuneration paid by Merus N.V., and compared it to remuneration at a group of similar sized companies.

Simply Wall St -

How Financially Strong Is Merus N.V. (NASDAQ:MRUS)?

(NASDAQ:MRUS), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … However, the trade-off is MRUS will have to follow strict debt obligations which will reduce its financial flexibility. … Is MRUS growing fast enough to value financial flexibility over lower cost of capital.

Simply Wall St -

One Thing To Remember About The Merus NV (NASDAQ:MRUS) Share Price

Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.

Simply Wall St -

Who Owns Most Of Merus NV (NASDAQ:MRUS)?

Today, I will be analyzing Merus NV’s (NASDAQ:MRUS) recent ownership structure, an important but not-so-popular subject among individual investors. … The implications of these institutions’ actions can either benefit or hinder individual investors, so it is important to understand the ownership composition of your stock investment. … Therefore, it is beneficial for us to examine MRUS's ownership structure in more detail.

Simply Wall St -

Merus NV (NASDAQ:MRUS): When Will It Breakeven?

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. … Many investors are wondering the rate at which MRUS will turn a profit, with the big question being “when will the company breakeven?” … Below I will provide a high-level summary of the industry analysts’ expectations for MRUS

Simply Wall St -

What Are Analysts Expecting From Merus NV. (NASDAQ:MRUS) In The Next Couple Of Years?

(NASDAQ:MRUS) announced its most recent earnings update, which confirmed that losses became smaller relative to the prrior year's level as a result of recent tailwinds Below is my commentary, albeit very simple and high-level, on how market analysts view Merus's earnings growth trajectory over the next few years and whether the future looks brighter. … NasdaqGM:MRUS Future Profit Jun 6th 18 While it is helpful to be aware of the growth each year relative to today’s value, it may be more valuable to analyze the rate at which the company is moving on average every year. … The slope of this line is the rate of earnings growth, which in this case is -3.98%.

Simply Wall St -

Merus NV. (NASDAQ:MRUS): Does The -54.76% Earnings Drop Reflect A Longer Term Trend?

After reading Merus NV.'s (NASDAQ:MRUS) most recent earnings announcement (31 December 2017), I found it useful to look back at how the company has performed in the past and compare this against the latest numbers. … For the purpose of this commentary, I like to use data from the most recent 12 months, which either annualizes the most recent 6-month earnings update, or in some cases, the most recent annual report is already the latest available financial data. … For Merus, its latest earnings (trailing twelve month) is -€73.09M, which, relative to the previous year's figure, has become more negative.

Simply Wall St -

Should You Invest In The Healthcare Sector And Merus NV. (NASDAQ:MRUS)?

This rate is larger than the growth rate of the US stock market as a whole. … NasdaqGM:MRUS PE PEG Gauge Apr 6th 18 The biotech industry is trading at a PE ratio of 26.06x, above the broader US stock market PE of 18.15x. … If Merus has been on your watchlist for a while, now may be the time to enter into the stock, if you like its growth prospects and are not highly concentrated in the biotech industry.

Simply Wall St -

When Will Merus NV. (NASDAQ:MRUS) Turn A Profit?

Many investors are wondering the rate at which MRUS will turn a profit, with the big question being “when will the company breakeven?” In this article, I will touch on the expectations for MRUS’s growth and when analysts expect the company to become profitable. … However, if this rate turns out to be too buoyant, MRUS may become profitable later than analysts predict. … Next Steps: This article is not intended to be a comprehensive analysis on MRUS, so if you are interested in understanding the company at a deeper level, take a look at MRUS’s company page on Simply Wall St.

Simply Wall St -

Company Info

Description

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II clinical trial for the treatment of gastric and non-small cell lung cancers. The company is also developing MCLA-117 that is in Phase I clinical trial for the treatment of patients with acute myeloid leukemia; and MCLA-158, which is in a Phase I clinical trial for the treatment of solid tumors with an initial focus on colorectal cancer. In addition, its research and development stage bispecific antibody candidates include MCLA-129, which is being developed in collaboration with Betta Pharmaceuticals Co. Ltd; MCLA-145, which is being developed in collaboration with Incyte Corporation; and clinical programs to explore new potential combination therapies or indication. The company was founded in 2003 and is headquartered in Utrecht, the Netherlands.

Details
Name: Merus N.V.
MRUS
Exchange: NasdaqGM
Founded: 2003
$359,637,262
29,003,005
Website: http://www.merus.nl
Address: Merus N.V.
Yalelaan 62,
Utrecht,
Utrecht, 3584 CM,
Netherlands
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM MRUS Common Stock Nasdaq Global Market US USD 19. May 2016
DB 2GH Common Stock Deutsche Boerse AG DE EUR 19. May 2016
Number of employees
Current staff
Staff numbers
110
Merus employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 03:14
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/25
Last earnings filing: 2020/03/16
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.